Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Date:11/8/2012

justed information is included with this press release.

Revenues and Product SalesTotal revenues for the quarter ended September 30, 2012 were $175.5 million, including net sales, royalties and contract revenues, but excluding the $8.1 million of net sales attributable to the divested women's health business that were reported separately as discontinued operations.  

A significant increase in total net sales for the third quarter of 2012 over the prior year third quarter resulted from the addition of net sales from the expanded product portfolio acquired in the Azur Pharma and EUSA Pharma transactions, as well as continued growth in net sales of Xyrem® (sodium oxybate) oral solution.Net sales from continuing operations for the third quarter of 2012 included:

  • Xyrem:  Net sales of Xyrem increased by 64% to $102.6 million for the third quarter of 2012, compared to net sales of $62.5 million in the third quarter of 2011. During the third quarter of 2012, the average number of active Xyrem patients was approximately 10,200.
  • Erwinaze/Erwinase: Worldwide net sales of Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) were $31.7 million.  Erwinaze was approved by the U.S. FDA in November 2011.
  • Prialt:  Third quarter 2012 net sales of Prialt® (ziconotide) intrathecal infusion were $5.4 million, compared to $5.0 million in the prior year quarter on a pro forma basis.
  • Psychiatry Products:  Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD, were $21.0 million for the third quarter of 2012.  Net sales of these products in the prior year quarter were $19.7 million on a pro forma basis.
  • Other:  Net sales of other products for the third
    '/>"/>

  • SOURCE Jazz Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
    2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
    3. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
    4. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
    5. Genoa Pharmaceuticals announces $1.2M Financing
    6. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
    7. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
    8. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
    9. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
    10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... , July 23 2014 Ampio Pharmaceuticals, ... its new headquarters, manufacturing and research facility: ... 80112 Direct: (720) 437-6500 ... efficient, pharmaceutical drug manufacturing facility will be fully operational ... the first batches of Ampion TM necessary to ...
    (Date:7/23/2014)... July 23, 2014  ArmaGen, a privately held ... treat severe neurological disorders, announced today that it ... agreement with Shire plc to develop AGT-182, an ... of both the central nervous system (CNS) and ... as MPS II, Hunter syndrome is a rare, ...
    (Date:7/22/2014)... - Investment to Foster Early Biotech Start-ups ... a fully-fledged oncology pharmaceutical company, announced on July 23 ... Remiges BioPharma Fund (hereinafter "Remiges Fund"), a newly formed ... long history of developing new therapeutic options to serve ... of TAS-102 is an example of our commitment to ...
    Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2
    (Date:7/23/2014)... (PRWEB) July 23, 2014 According to ... Market by Form Factor (Integrated Circuit IP, SOC IP), ... DSP), Application, Geography and Verification IP - Forecast & ... market is expected to grow at a CAGR of ... in 2020. , Browse more than 76 market data ...
    (Date:7/23/2014)... The Centers for Disease Control and Prevention ... from 2010 to 2012. Formerly known as “the nation’s ... access to some of the strongest opiates, such as Oxycontin, ... enforcement launched an initiative to crack down on these rampant ... 65 that existed in the state just a few years ...
    (Date:7/23/2014)... Asian women has identified three genetic changes linked to ... by Vanderbilt University investigators, was published online July 20 ... is one of the most common malignancies among women ... the disease have focused on women of European ancestry. ... exposures between East Asian women and those of European ...
    (Date:7/23/2014)... 2014 The Circuelle Foundation compiled ... institutions uncovering the importance of breast self-exams (BSE). ... for breast self-exams is contradictory and can be ... for keeping this healthy ritual. , “Women are ... significance of breast self-exams and becoming breast aware,” ...
    (Date:7/23/2014)... 23, 2014 Five years ago, when the ... were few options for babies diagnosed with a medical condition ... across the country for innovative fetal therapies. Since then, nearly ... to care for their babies in the womb, and the ... , “A number of the babies we see are ...
    Breaking Medicine News(10 mins):Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:Historical and Current Research Points to Importance of Breast Self-Exams 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2
    ... , ATLANTA, Aug. 20 During this ... and treatment of infertility with ovulation induction and insemination, surgery ... and financial aspects. Discussions include information about age related infertility, ... donor sperm or donor eggs. , , ...
    ... series of Featured Clinical Trials will be presented at ... trials. These featured clinical trials represent groundbreaking research and ... field of interventional cardiology. WHEN:,The TCT Featured ... from 2:00 6:00 pm. Session I. ...
    ... in Canadian study , THURSDAY, Aug. 20 (HealthDay News) ... of women with abnormal Pap tests receive proper follow-up care ... cervical cancer than high-income women, a new study has found. ... of cancer, yet in Ontario more than 1 million women ...
    ... New ... , ... 20, 2009 -- ConnextionsHealth today introduced the Rapid Ramp Call Verification Solution to ... and Medicaid Services (CMS). The guideline , issued August 7, 2009, and effective for ...
    ... PHOENIX, Aug. 20 A special screening of Shooting Beauty , ... Film Festival, will take place on Thursday, September 17th at 7:00pm at ... benefit UCP of Central Arizona and the Phoenix Film Foundation, two non-profit ... and can be purchased at www . brownp ...
    ... release is available in German . , ... has investigated the reliability of diagnosing bronchial asthma in children ... the test results can have for these patients. IQWiG published ... the available studies do not reveal any diagnostic procedure to ...
    Cached Medicine News:Health News:CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco 2Health News:Better Pap Smear Follow-Up Needed Among Lower-Income Women 2Health News:ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution 2Health News:ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution 3Health News:Film Event to Support United Cerebral Palsy (UCP) of Central Arizona and the Phoenix Film Foundation 2Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 2Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 3Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 4
    ... Electrohydraulic Lithotriptor combines efficient stone fragmentation, low ... a large, clear LED display, automatic probe ... according to probe size. In addition, the ... end-of-life, and can also regulate and control ...
    Electrohydraulic Lithotripsy Probe for AEH-2 & AEH-3...
    Short double-horn bridge for insertion of instruments...
    Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha...
    Medicine Products: